Fgf9 signaling regulates small intestinal elongation and mesenchymal development

Michael J. Geske, Xiuqin Zhang, Khushbu K. Patel, David M. Ornitz, Thaddeus S. Stappenbeck

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Short bowel syndrome is an acquired condition in which the length of the small intestine is insufficient to perform its normal absorptive function. Current therapies are limited as the developmental mechanisms that normally regulate elongation of the small intestine are poorly understood. Here, we identify Fgf9 as an important epithelial-to-mesenchymal signal required for proper small intestinal morphogenesis. Mouse embryos that lack either Fgf9 or the mesenchymal receptors for Fgf9 contained a disproportionately shortened small intestine, decreased mesenchymal proliferation, premature differentiation of fibroblasts into myofibroblasts and significantly elevated Tgfβ signaling. These findings suggest that Fgf9 normally functions to repress Tgfβ signaling in these cells. In vivo, a small subset of mesenchymal cells expressed phospho-Erk and the secreted Tgfβ inhibitors Fst and Fstl1 in an Fgf9-dependent fashion. The p-Erk/Fst/Fstl1-expressing cells were most consistent with intestinal mesenchymal stem cells (iMSCs). We found that isolated iMSCs expressed p-Erk, Fst and Fstl1, and could repress the differentiation of intestinal myofibroblasts in co-culture. These data suggest a model in which epithelial-derived Fgf9 stimulates iMSCs that in turn regulate underlying mesenchymal fibroblast proliferation and differentiation at least in part through inhibition of Tgfβ signaling in the mesenchyme. Taken together, the interaction of FGF and TGFβ signaling pathways in the intestinal mesenchyme could represent novel targets for future short bowel syndrome therapies.

Original languageEnglish (US)
Pages (from-to)2959-2968
Number of pages10
JournalDevelopment
Volume135
Issue number17
DOIs
StatePublished - Sep 1 2008

Fingerprint

Mesenchymal Stromal Cells
Small Intestine
Short Bowel Syndrome
Myofibroblasts
Mesoderm
Fibroblasts
Coculture Techniques
Morphogenesis
Embryonic Structures
Therapeutics

Keywords

  • Epithelial-mesenchymal crosstalk
  • Fibroblast growth factor 9 (Fgf9)
  • Follistatin
  • Gut development
  • Mesenchymal stem cells
  • Mouse
  • Tgfβ signaling

ASJC Scopus subject areas

  • Molecular Biology
  • Developmental Biology

Cite this

Geske, M. J., Zhang, X., Patel, K. K., Ornitz, D. M., & Stappenbeck, T. S. (2008). Fgf9 signaling regulates small intestinal elongation and mesenchymal development. Development, 135(17), 2959-2968. https://doi.org/10.1242/dev.020453

Fgf9 signaling regulates small intestinal elongation and mesenchymal development. / Geske, Michael J.; Zhang, Xiuqin; Patel, Khushbu K.; Ornitz, David M.; Stappenbeck, Thaddeus S.

In: Development, Vol. 135, No. 17, 01.09.2008, p. 2959-2968.

Research output: Contribution to journalArticle

Geske, MJ, Zhang, X, Patel, KK, Ornitz, DM & Stappenbeck, TS 2008, 'Fgf9 signaling regulates small intestinal elongation and mesenchymal development', Development, vol. 135, no. 17, pp. 2959-2968. https://doi.org/10.1242/dev.020453
Geske, Michael J. ; Zhang, Xiuqin ; Patel, Khushbu K. ; Ornitz, David M. ; Stappenbeck, Thaddeus S. / Fgf9 signaling regulates small intestinal elongation and mesenchymal development. In: Development. 2008 ; Vol. 135, No. 17. pp. 2959-2968.
@article{958008d2a5604176b8072fb31fef34eb,
title = "Fgf9 signaling regulates small intestinal elongation and mesenchymal development",
abstract = "Short bowel syndrome is an acquired condition in which the length of the small intestine is insufficient to perform its normal absorptive function. Current therapies are limited as the developmental mechanisms that normally regulate elongation of the small intestine are poorly understood. Here, we identify Fgf9 as an important epithelial-to-mesenchymal signal required for proper small intestinal morphogenesis. Mouse embryos that lack either Fgf9 or the mesenchymal receptors for Fgf9 contained a disproportionately shortened small intestine, decreased mesenchymal proliferation, premature differentiation of fibroblasts into myofibroblasts and significantly elevated Tgfβ signaling. These findings suggest that Fgf9 normally functions to repress Tgfβ signaling in these cells. In vivo, a small subset of mesenchymal cells expressed phospho-Erk and the secreted Tgfβ inhibitors Fst and Fstl1 in an Fgf9-dependent fashion. The p-Erk/Fst/Fstl1-expressing cells were most consistent with intestinal mesenchymal stem cells (iMSCs). We found that isolated iMSCs expressed p-Erk, Fst and Fstl1, and could repress the differentiation of intestinal myofibroblasts in co-culture. These data suggest a model in which epithelial-derived Fgf9 stimulates iMSCs that in turn regulate underlying mesenchymal fibroblast proliferation and differentiation at least in part through inhibition of Tgfβ signaling in the mesenchyme. Taken together, the interaction of FGF and TGFβ signaling pathways in the intestinal mesenchyme could represent novel targets for future short bowel syndrome therapies.",
keywords = "Epithelial-mesenchymal crosstalk, Fibroblast growth factor 9 (Fgf9), Follistatin, Gut development, Mesenchymal stem cells, Mouse, Tgfβ signaling",
author = "Geske, {Michael J.} and Xiuqin Zhang and Patel, {Khushbu K.} and Ornitz, {David M.} and Stappenbeck, {Thaddeus S.}",
year = "2008",
month = "9",
day = "1",
doi = "10.1242/dev.020453",
language = "English (US)",
volume = "135",
pages = "2959--2968",
journal = "Development (Cambridge)",
issn = "0950-1991",
publisher = "Company of Biologists Ltd",
number = "17",

}

TY - JOUR

T1 - Fgf9 signaling regulates small intestinal elongation and mesenchymal development

AU - Geske, Michael J.

AU - Zhang, Xiuqin

AU - Patel, Khushbu K.

AU - Ornitz, David M.

AU - Stappenbeck, Thaddeus S.

PY - 2008/9/1

Y1 - 2008/9/1

N2 - Short bowel syndrome is an acquired condition in which the length of the small intestine is insufficient to perform its normal absorptive function. Current therapies are limited as the developmental mechanisms that normally regulate elongation of the small intestine are poorly understood. Here, we identify Fgf9 as an important epithelial-to-mesenchymal signal required for proper small intestinal morphogenesis. Mouse embryos that lack either Fgf9 or the mesenchymal receptors for Fgf9 contained a disproportionately shortened small intestine, decreased mesenchymal proliferation, premature differentiation of fibroblasts into myofibroblasts and significantly elevated Tgfβ signaling. These findings suggest that Fgf9 normally functions to repress Tgfβ signaling in these cells. In vivo, a small subset of mesenchymal cells expressed phospho-Erk and the secreted Tgfβ inhibitors Fst and Fstl1 in an Fgf9-dependent fashion. The p-Erk/Fst/Fstl1-expressing cells were most consistent with intestinal mesenchymal stem cells (iMSCs). We found that isolated iMSCs expressed p-Erk, Fst and Fstl1, and could repress the differentiation of intestinal myofibroblasts in co-culture. These data suggest a model in which epithelial-derived Fgf9 stimulates iMSCs that in turn regulate underlying mesenchymal fibroblast proliferation and differentiation at least in part through inhibition of Tgfβ signaling in the mesenchyme. Taken together, the interaction of FGF and TGFβ signaling pathways in the intestinal mesenchyme could represent novel targets for future short bowel syndrome therapies.

AB - Short bowel syndrome is an acquired condition in which the length of the small intestine is insufficient to perform its normal absorptive function. Current therapies are limited as the developmental mechanisms that normally regulate elongation of the small intestine are poorly understood. Here, we identify Fgf9 as an important epithelial-to-mesenchymal signal required for proper small intestinal morphogenesis. Mouse embryos that lack either Fgf9 or the mesenchymal receptors for Fgf9 contained a disproportionately shortened small intestine, decreased mesenchymal proliferation, premature differentiation of fibroblasts into myofibroblasts and significantly elevated Tgfβ signaling. These findings suggest that Fgf9 normally functions to repress Tgfβ signaling in these cells. In vivo, a small subset of mesenchymal cells expressed phospho-Erk and the secreted Tgfβ inhibitors Fst and Fstl1 in an Fgf9-dependent fashion. The p-Erk/Fst/Fstl1-expressing cells were most consistent with intestinal mesenchymal stem cells (iMSCs). We found that isolated iMSCs expressed p-Erk, Fst and Fstl1, and could repress the differentiation of intestinal myofibroblasts in co-culture. These data suggest a model in which epithelial-derived Fgf9 stimulates iMSCs that in turn regulate underlying mesenchymal fibroblast proliferation and differentiation at least in part through inhibition of Tgfβ signaling in the mesenchyme. Taken together, the interaction of FGF and TGFβ signaling pathways in the intestinal mesenchyme could represent novel targets for future short bowel syndrome therapies.

KW - Epithelial-mesenchymal crosstalk

KW - Fibroblast growth factor 9 (Fgf9)

KW - Follistatin

KW - Gut development

KW - Mesenchymal stem cells

KW - Mouse

KW - Tgfβ signaling

UR - http://www.scopus.com/inward/record.url?scp=52249096620&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52249096620&partnerID=8YFLogxK

U2 - 10.1242/dev.020453

DO - 10.1242/dev.020453

M3 - Article

C2 - 18653563

AN - SCOPUS:52249096620

VL - 135

SP - 2959

EP - 2968

JO - Development (Cambridge)

JF - Development (Cambridge)

SN - 0950-1991

IS - 17

ER -